Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.32 Insider Own1.80% Shs Outstand88.22M Perf Week-3.98%
Market Cap3.60B Forward P/E- EPS next Y-1.03 Insider Trans-2.01% Shs Float81.73M Perf Month12.10%
Income-109.90M PEG- EPS next Q-0.32 Inst Own73.50% Short Float8.06% Perf Quarter14.72%
Sales257.10M P/S14.02 EPS this Y13.60% Inst Trans5.24% Short Ratio9.04 Perf Half Y-1.74%
Book/sh5.20 P/B8.03 EPS next Y23.10% ROA-12.60% Target Price59.25 Perf Year-7.55%
Cash/sh6.21 P/C6.73 EPS next 5Y- ROE-20.00% 52W Range22.65 - 48.95 Perf YTD-2.61%
Dividend- P/FCF- EPS past 5Y22.50% ROI-15.30% 52W High-14.67% Beta1.58
Dividend %- Quick Ratio11.00 Sales past 5Y13.30% Gross Margin99.20% 52W Low84.42% ATR1.73
Employees531 Current Ratio11.10 Sales Q/Q2.10% Oper. Margin-47.20% RSI (14)56.24 Volatility3.04% 4.33%
OptionableYes Debt/Eq0.14 EPS Q/Q-67.60% Profit Margin-42.70% Rel Volume0.33 Prev Close41.82
ShortableYes LT Debt/Eq0.11 EarningsMay 07 AMC Payout- Avg Volume728.67K Price41.77
Recom2.00 SMA202.09% SMA5010.16% SMA2006.26% Volume241,638 Change-0.12%
Jul-10-20Resumed Stifel Buy $71
May-01-20Initiated Cowen Market Perform $40
Apr-27-20Initiated BofA/Merrill Neutral $45
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
Jun-24-20 12:00PM  
FibroGen Begins Phase II Study for Acute Coronavirus in US
Zacks
Jun-23-20 04:05PM  
Sarepta Addressing Gene Therapy Issue With Two Acquisitions
GuruFocus.com
07:00AM  
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
GlobeNewswire
Jun-22-20 07:00AM  
FibroGen Appoints Thane Wettig as Chief Commercial Officer
GlobeNewswire +5.78%
Jun-16-20 09:20AM  
Hedge Funds Are Nibbling On FibroGen Inc (FGEN)
Insider Monkey
Jun-15-20 10:42AM  
Weekly CEO Buys Highlight: Camping World, FibroGen
GuruFocus.com
Jun-10-20 08:37PM  
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher
Zacks
Jun-09-20 10:17AM  
FibroGen Initiates Phase II/III Study in Severe Coronavirus
Zacks +6.49%
Jun-08-20 05:00PM  
FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress
GlobeNewswire
07:00AM  
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
GlobeNewswire
May-27-20 07:00AM  
FibroGen to Present at Upcoming Investor Conferences
GlobeNewswire
May-21-20 07:00AM  
European Medicines Agency Accepts Astellas Marketing Authorization Application for Roxadustat
GlobeNewswire
May-20-20 10:00PM  
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat
PR Newswire +6.07%
May-11-20 06:32AM  
FibroGen, Inc. (NASDAQ:FGEN) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Simply Wall St. +8.76%
May-09-20 05:01PM  
FibroGen Inc (FGEN) Q1 2020 Earnings Call Transcript
Motley Fool
01:42AM  
Edited Transcript of FGEN earnings conference call or presentation 7-May-20 9:00pm GMT
Thomson Reuters StreetEvents
May-08-20 07:00AM  
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
GlobeNewswire
May-07-20 08:40PM  
FibroGen (FGEN) Reports Q1 Loss, Lags Revenue Estimates
Zacks
04:01PM  
FibroGen Reports First Quarter 2020 Financial Results
GlobeNewswire
11:24AM  
Akebia Shares Climb on Positive Anemia Drug Study Results
GuruFocus.com
May-06-20 08:43AM  
Why FibroGen (FGEN) Might Surprise This Earnings Season
Zacks
May-03-20 10:17AM  
How Does Investing In FibroGen, Inc. (NASDAQ:FGEN) Impact The Volatility Of Your Portfolio?
Simply Wall St.
Apr-30-20 12:33PM  
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks -7.22%
Apr-24-20 07:00AM  
FibroGen To Report First Quarter 2020 Financial Results
GlobeNewswire
Apr-21-20 05:31PM  
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
GuruFocus.com
Apr-20-20 07:00AM  
FibroGen Reports UK Court Ruling
GlobeNewswire
Mar-27-20 02:52PM  
Hedge Funds Were Selling FibroGen Inc (FGEN) Before The Coronavirus
Insider Monkey
Mar-24-20 04:23PM  
Biotech stocks have held up better than the broader market and these five are potential winners
MarketWatch +12.38%
Mar-04-20 07:07AM  
Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results
Simply Wall St. +6.21%
Mar-03-20 08:13PM  
Edited Transcript of FGEN earnings conference call or presentation 2-Mar-20 10:00pm GMT
Thomson Reuters StreetEvents -8.55%
05:50PM  
After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push
American City Business Journals
Mar-02-20 05:15PM  
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
Zacks
04:01PM  
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
GlobeNewswire
Feb-24-20 12:30PM  
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
Zacks
Feb-18-20 07:00AM  
FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results
GlobeNewswire
Feb-12-20 09:45AM  
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
Zacks
09:18AM  
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
Benzinga
Feb-11-20 05:00PM  
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
GlobeNewswire
08:00AM  
FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference
GlobeNewswire
Feb-03-20 03:42PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of FibroGen, Inc. - FGEN
GlobeNewswire
Jan-31-20 09:12AM  
FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet
Simply Wall St.
Jan-30-20 12:01AM  
Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan
PR Newswire
Jan-13-20 05:59PM  
2019 Review: Top Hedge Fund Stocks vs. FibroGen Inc (FGEN)
Insider Monkey
Jan-06-20 06:03PM  
Four months after CEO's death, biotech company names Lilly vet as leader
American City Business Journals
07:00AM  
FibroGen Names Enrique Conterno as Chief Executive Officer
GlobeNewswire
Dec-24-19 08:55AM  
Are Options Traders Betting on a Big Move in FibroGen (FGEN) Stock?
Zacks
Dec-23-19 05:42PM  
Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requests
American City Business Journals
07:00AM  
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
GlobeNewswire
Dec-17-19 06:45AM  
Is FibroGen's (NASDAQ:FGEN) 136% Share Price Increase Well Justified?
Simply Wall St.
Dec-06-19 10:03AM  
Hedge Funds Have Never Been This Bullish On FibroGen Inc (FGEN)
Insider Monkey
Dec-02-19 07:00AM  
FibroGen Announces Roxadustat Inclusion in Chinas National Reimbursement Drug List
GlobeNewswire
Nov-15-19 02:20PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
ACCESSWIRE +5.75%
Nov-14-19 07:42PM  
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Business Wire
05:24PM  
Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT
Thomson Reuters StreetEvents
Nov-13-19 08:03PM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud
GlobeNewswire
07:00PM  
Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors
Business Wire
06:19PM  
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors
Business Wire
02:00PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
ACCESSWIRE
Nov-11-19 05:15PM  
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
Zacks -14.94%
05:10PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
GlobeNewswire
04:01PM  
FibroGen Reports Third Quarter 2019 Financial Results
GlobeNewswire
09:21AM  
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session
Zacks
Nov-08-19 02:10PM  
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
GlobeNewswire +9.61%
01:45PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
ACCESSWIRE
08:14AM  
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
Benzinga
Nov-07-19 04:39PM  
FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease
GlobeNewswire
Nov-06-19 10:41AM  
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss
Zacks
10:36AM  
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
Zacks
09:52AM  
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN)
ACCESSWIRE
08:52AM  
Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%
Zacks
Nov-05-19 10:18PM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud
PR Newswire +8.00%
05:24PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
GlobeNewswire
11:17AM  
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance
Zacks
10:42AM  
Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y
Zacks
Nov-04-19 04:38PM  
FibroGen, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
GlobeNewswire -7.52%
07:00AM  
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
GlobeNewswire
Oct-31-19 06:53AM  
5 Stocks With High Net Income Ratio to Grab Now
Zacks
Oct-24-19 12:17PM  
Is FibroGen Inc (FGEN) Going To Burn These Hedge Funds ?
Insider Monkey
08:17AM  
Does Market Volatility Impact FibroGen, Inc.'s (NASDAQ:FGEN) Share Price?
Simply Wall St.
Oct-23-19 07:00AM  
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer
GlobeNewswire
Oct-17-19 11:20AM  
Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock
Zacks
Oct-16-19 08:45AM  
5 Stocks With High Net Income Ratio to Scoop Up
Zacks
Oct-11-19 10:58AM  
Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019
GlobeNewswire
Oct-07-19 05:57PM  
FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine
GlobeNewswire
06:41AM  
UK and US scientists win Nobel Medicine Prize
Financial Times
Oct-03-19 10:59AM  
FibroGen Enters Oversold Territory
Zacks
09:42AM  
Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%
Zacks
Sep-30-19 08:00PM  
FibroGen Receives One of China Pharmaceutical Industrys Highest Awards for Clinical Innovation for Roxadustat
GlobeNewswire
07:00AM  
FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis
GlobeNewswire
Sep-27-19 11:03AM  
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
Zacks
Sep-26-19 11:16AM  
Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
Zacks
09:00AM  
BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
Zacks
07:00AM  
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
GlobeNewswire
Sep-25-19 08:34AM  
Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%
Zacks
Sep-23-19 01:20PM  
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
Zacks
12:36PM  
Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
Zacks
Sep-20-19 11:54AM  
FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD
Zacks
03:05AM  
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
GlobeNewswire
03:00AM  
Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
PR Newswire
Sep-18-19 08:13AM  
Is FibroGen, Inc.'s (NASDAQ:FGEN) 7.6% ROE Worse Than Average?
Simply Wall St.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cotroneo PatSVP, Finance and CFOJun 16Sale39.683,928155,863271,060Jun 18 06:35 PM
Conterno Enrique AChief Executive OfficerJun 11Buy35.2819,800698,59927,800Jun 12 06:59 AM
Conterno Enrique AChief Executive OfficerJun 10Buy36.298,000290,2828,000Jun 12 06:59 AM
Rosenkranz Roberto PedroDirectorJun 09Option Exercise23.8524,000572,40096,100Jun 11 09:22 PM
Chung ChristineSVP, China OperationsMar 19Option Exercise25.407,345186,563166,358Mar 19 07:55 PM
KEARNS THOMAS F JRDirectorMar 19Option Exercise2.9018,00052,200161,464Mar 23 05:37 PM
KEARNS THOMAS F JRDirectorMar 19Sale23.1718,000417,074143,464Mar 23 05:37 PM
Chung ChristineSVP, China OperationsMar 19Sale25.917,345190,282159,013Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Option Exercise25.4040010,160162,918Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Sale24.793,90596,799159,013Mar 19 07:55 PM
Yu K PeonyChief Medical OfficerMar 16Option Exercise19.393,75072,713166,541Mar 18 08:05 PM
Cotroneo PatSVP, Finance and CFOMar 16Sale26.369,239243,540236,466Mar 18 08:00 PM
Chung ChristineSVP, China OperationsFeb 12Option Exercise25.405,625142,875138,269Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 12Sale45.985,625258,617132,644Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 11Option Exercise25.405,625142,875138,269Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 11Sale44.485,625250,200132,644Feb 13 05:36 PM
Kurkijarvi KaleviDirectorFeb 10Option Exercise18.346,000110,04034,400Feb 12 09:52 PM
Kurkijarvi KaleviDirectorFeb 10Sale42.696,000256,14028,400Feb 12 09:52 PM
Chung ChristineSVP, China OperationsJan 07Option Exercise25.405,625142,875138,269Jan 08 09:12 PM
Chung ChristineSVP, China OperationsJan 07Sale42.765,625240,525132,644Jan 08 09:12 PM
Chung ChristineSVP, China OperationsJan 06Option Exercise25.405,625142,875138,269Jan 08 09:12 PM
Kurkijarvi KaleviDirectorJan 06Option Exercise18.006,000108,00034,400Jan 08 09:14 PM
Kurkijarvi KaleviDirectorJan 06Sale42.666,000255,96028,400Jan 08 09:14 PM
Chung ChristineSVP, China OperationsJan 06Sale42.985,625241,763132,644Jan 08 09:12 PM
Cotroneo PatSVP, Finance and CFODec 20Option Exercise7.8156,254439,427310,042Dec 26 04:25 PM
Cotroneo PatSVP, Finance and CFODec 20Sale45.6759,4562,715,517250,586Dec 26 04:25 PM
Chung ChristineSVP, China OperationsDec 17Option Exercise25.405,625142,875138,269Dec 18 08:33 PM
Chung ChristineSVP, China OperationsDec 17Sale46.985,625264,244132,644Dec 18 08:33 PM
Chung ChristineSVP, China OperationsDec 16Option Exercise25.402,12053,848138,269Dec 18 08:33 PM
Chung ChristineSVP, China OperationsDec 16Sale47.085,625264,832132,644Dec 18 08:33 PM
Yu K PeonyChief Medical OfficerDec 16Sale46.683,420159,646172,617Dec 17 08:38 PM
Kurkijarvi KaleviDirectorDec 09Option Exercise18.006,000108,00034,400Dec 12 06:08 PM
Kurkijarvi KaleviDirectorDec 09Sale47.506,000285,00028,400Dec 12 06:08 PM
Yu K PeonyChief Medical OfficerDec 04Option Exercise17.464,15772,576179,397Dec 06 07:51 PM
Chung ChristineSVP, China OperationsNov 14Option Exercise21.845,625122,838145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 14Sale34.745,625195,440139,628Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Option Exercise19.395,625109,069145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Sale34.545,625194,288139,628Nov 15 06:07 PM
Cotroneo PatSVP, Finance and CFONov 08Option Exercise2.9012,50036,250256,932Nov 12 09:15 PM
Kurkijarvi KaleviDirectorNov 07Option Exercise9.786,00058,65034,400Nov 08 06:05 PM
Kurkijarvi KaleviDirectorNov 07Sale38.276,000229,62428,400Nov 08 06:05 PM
Chung ChristineSVP, China OperationsOct 09Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 09Sale36.585,625205,763139,628Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Sale36.785,625206,914139,628Oct 10 07:57 PM
Kurkijarvi KaleviDirectorOct 07Option Exercise9.786,00058,65034,400Oct 09 08:26 PM
Kurkijarvi KaleviDirectorOct 07Sale36.736,000220,38028,400Oct 09 08:26 PM
Chung ChristineSVP, China OperationsSep 20Option Exercise19.395,625109,069145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 20Sale39.875,625224,269139,628Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Option Exercise19.392,12041,107145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Sale40.455,625227,550139,628Sep 23 06:57 PM
Cotroneo PatSVP, Finance and CFOSep 17Sale41.383,201132,457244,432Sep 18 07:42 PM
Yu K PeonyChief Medical OfficerSep 16Sale40.923,419139,905175,240Sep 18 07:45 PM
Kurkijarvi KaleviDirectorSep 09Option Exercise5.956,00035,70034,400Sep 10 08:29 PM
Kurkijarvi KaleviDirectorSep 09Sale40.956,000245,72328,400Sep 10 08:29 PM
Chung ChristineSVP, China OperationsAug 23Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 23Sale42.515,625239,099151,570Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Option Exercise2.906,83419,8192,345,012Aug 23 04:49 PM
Chung ChristineSVP, China OperationsAug 22Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 22Sale43.845,625246,583151,570Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.771,41862,06644,238Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.8718,400807,1292,326,612Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Option Exercise2.906,83419,8192,356,578Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.811,41863,54145,656Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.7918,400824,1362,338,178Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 13Option Exercise2.906,83419,8192,368,144Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.611,41864,68047,074Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.6518,400840,0062,349,744Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Option Exercise2.906,83419,8192,379,710Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.171,41864,05648,492Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.2418,400832,3292,361,310Aug 14 05:38 PM
Kurkijarvi KaleviDirectorAug 05Option Exercise3.506,00021,00034,400Aug 07 04:42 PM
Kurkijarvi KaleviDirectorAug 05Sale45.226,000271,32028,400Aug 07 04:42 PM
Neff Thomas BChief Executive OfficerJul 25Option Exercise2.906,83419,8192,391,276Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.881,41866,47249,910Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.9518,400863,8582,372,876Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Option Exercise2.906,83419,8192,402,842Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.571,41866,03651,328Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.5418,400856,3362,384,442Jul 26 05:31 PM
Chung ChristineSVP, China OperationsJul 11Option Exercise28.215,625158,663157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 11Option Exercise2.906,83419,8192,414,408Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.091,41863,93852,746Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.1518,400830,8362,396,008Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 11Sale45.145,625253,915151,570Jul 12 04:23 PM
open in yahoo | open in reuters | open in google